Humacyte (HUMA) Free Cash Flow (2020 - 2026)
Humacyte (HUMA) posted quarterly Free Cash Flow of -$25.3 million for Q1 2026, up 13.28% year-over-year from -$22.3 million in Q1 2025, and up 3.24% quarter-over-quarter from -$26.1 million in Q4 2025.
Humacyte (HUMA) Free Cash Flow (2020 - 2026) Analysis & Trends
Humacyte (HUMA) has reported Free Cash Flow for 7 consecutive years, with -$25.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Free Cash Flow rose 13.28% year-over-year to -$25.3 million; the TTM figure through Mar 2026 stood at -$102.0 million (down 0.93% YoY), while the FY2025 annual figure was -$105.9 million, down 6.23% from the prior year.
- Free Cash Flow climbed to -$25.3 million in Q1 2026 per HUMA's latest filing, from -$26.1 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$13.5 million in Q3 2023 and bottomed at -$29.1 million in Q1 2025.
- Historically, Free Cash Flow has averaged -$22.3 million across 5 years, with a median of -$23.1 million in 2023.
- Annual changes were most pronounced in 2022 — Free Cash Flow surged 44.62% — and 2024, when it tumbled 76.6%.
- Humacyte's Free Cash Flow stood at -$19.8 million in 2022, then climbed by 2.94% to -$19.2 million in 2023, then slumped by 38.64% to -$26.6 million in 2024, then increased by 1.87% to -$26.1 million in 2025, then advanced by 3.24% to -$25.3 million in 2026.
- Business Quant data shows HUMA's Free Cash Flow at -$25.3 million in Q1 2026, -$26.1 million in Q4 2025, and -$24.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Humacyte | 150.77 Mn | 150.77 Mn | -825,000.00 | -22.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -22.20 Mn |
| Jun 30, 2026 | -22.20 Mn |
| Mar 31, 2026 | -25.28 Mn |
| Mar 31, 2026 | -25.28 Mn |
| Dec 31, 2025 | -26.12 Mn |
| Dec 31, 2025 | -26.12 Mn |
| Sep 30, 2025 | -23.95 Mn |
| Sep 30, 2025 | -23.95 Mn |
| Jun 30, 2025 | -26.67 Mn |
| Jun 30, 2025 | -26.67 Mn |
| Mar 31, 2025 | -29.15 Mn |
| Mar 31, 2025 | -29.15 Mn |
| Dec 31, 2024 | -26.62 Mn |
| Dec 31, 2024 | -26.62 Mn |
| Sep 30, 2024 | -23.84 Mn |
| Sep 30, 2024 | -23.84 Mn |
| Jun 30, 2024 | -21.48 Mn |
| Jun 30, 2024 | -21.48 Mn |
| Mar 31, 2024 | -27.74 Mn |
| Mar 31, 2024 | -27.74 Mn |